Untargeted metabolomics platform for quantifying nootropic effects on cognitive function

Overview

This solution offers an analytical platform that applies untargeted metabolomics combined with chemometric analysis to objectively measure the metabolic effects of nootropic compounds on cognitive function. By using patient-derived brain organoids as a model system, the platform captures the broad metabolic landscape produced in response to substances such as caffeine, DHA, EPA, taurine, and creatine, providing a biological assessment of cognitive performance that is currently difficult to quantify. The approach is being developed to support translational research into cognitive enhancement and to investigate treatment options for intellectual disorders associated with X chromosome deletions, where cognitive defects, developmental delays, and autism are primary symptoms.

Technical specifications

Key capabilities:

• Untargeted metabolomic profiling methods capable of capturing a broad range of metabolites from neural cell cultures
• Chemometric analysis pipeline combining univariate and multivariate statistical techniques to identify significantly different metabolites
• Metabolic pathway mapping to elucidate mechanisms of action and identify biomarkers linked to cognitive function
• Brain organoid model system using patient-derived induced pluripotent stem cells, including models of X chromosome deletion disorders
• Capacity to test nootropic substances alone and in combination with vitamin B cofactors such as pyridoxine and folate
• Comparative analysis framework for evaluating treatments such as docosahexaenoic acid against untreated controls

Research insights to date:

• Preliminary work has identified pyridoxine as playing a key role in cellular repair associated with improved cognitive function
• The platform supports systematic evaluation of multiple nootropic compounds at varying concentrations

Technology readiness level

The platform is at an early-to-mid stage of development. Metabolomic profiling methods and chemometric analysis pipelines have been developed and applied in preliminary studies comparing treated and untreated neural cells. Future validation will expand testing across healthy and affected iPSC-derived neural cells treated with multiple nootropic compounds and vitamin B supplements, with the goal of generating metabolic maps and biomarkers that can translate to human clinical trials. The work is positioned to bridge laboratory discovery with clinical research in cognitive function and neurodevelopmental disorders.